| Bioactivity | Plozasiran is an siRNA targeting APOC3 for the study of mixed hyperlipidemia. |
| CAS | 2379776-40-4 |
| Molar Mass | 15618.77 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial. JAMA Cardiol. 2024;9(7):620-630. [2]. Gaudet D, Clifton P, Sullivan D, et al. RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia. NEJM Evid. 2023;2(12):EVIDoa2200325. |